Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beigene Ltd ADR
(NQ:
BGNE
)
156.39
+1.31 (+0.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey
April 21, 2022
From
BeiGene
Via
Business Wire
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series
April 19, 2022
From
BeiGene
Via
Business Wire
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
April 15, 2022
From
BeiGene
Via
Business Wire
IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
April 11, 2022
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022
April 08, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC
April 06, 2022
From
BeiGene
Via
Business Wire
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia
March 15, 2022
From
BeiGene
Via
Business Wire
BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
February 25, 2022
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia
February 22, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma
February 22, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia
February 17, 2022
From
BeiGene
Via
Business Wire
BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference
February 08, 2022
From
BeiGene, Ltd.
Via
Business Wire
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
February 01, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation
January 28, 2022
From
BeiGene
Via
Business Wire
Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential
January 24, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 24, 2022 – USA News Group – Within the grand battle against cancer, the use of immunotherapy continues to grow at...
Via
FinancialNewsMedia
BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer
January 24, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia
January 20, 2022
From
BeiGene
Via
Business Wire
BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference
January 06, 2022
From
BeiGene, Ltd.
Via
Business Wire
China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
January 06, 2022
From
BeiGene
Via
Business Wire
BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene’s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets
December 20, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
December 14, 2021
From
BeiGene, Ltd.
Via
Business Wire
Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of China
December 13, 2021
From
BeiGene
Via
Business Wire
BeiGene Presents Results from SEQUOIA Trial of BRUKINSA (zanubrutinib) in First-Line Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting
December 12, 2021
From
BeiGene
Via
Business Wire
BeiGene Presents Updated Safety and Efficacy Findings on BRUKINSA (zanubrutinib) in BTK Inhibitor-Intolerant Patients with Relapsed or Refractory B-Cell Malignancies
December 11, 2021
From
BeiGene
Via
Business Wire
BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021
December 10, 2021
From
BeiGene
Via
Business Wire
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
December 02, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in Three New Indications, BRUKINSA® (Zanubrutinib) in One New Indication, and the First Listing for Pamiparib
December 02, 2021
From
BeiGene
Via
Business Wire
BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021
December 02, 2021
From
BeiGene
Via
Business Wire
BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
November 30, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström’s Macroglobulinemia
November 23, 2021
From
BeiGene
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.